Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

EGFR tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC) patients is inevitable. Identification of resistance mechanisms and corresponding targeting strategies can lead to more successful later-line treatment in many patients. Using spectrometry-based proteomics, we iden...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:NPJ Precis Oncol
Prif Awduron: Terp, Mikkel G., Jacobsen, Kirstine, Molina, Miguel Angel, Karachaliou, Niki, Beck, Hans C., Bertran-Alamillo, Jordi, Giménez-Capitán, Ana, Cardona, Andrés F., Rosell, Rafael, Ditzel, Henrik J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2021
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282882/
https://ncbi.nlm.nih.gov/pubmed/34267282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00208-w
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg